Piervincenzi, Claudia https://orcid.org/0000-0002-7732-2062
Ojha, Abhineet
Tommasin, Silvia
Satriano, Federica
Petsas, Nikolaos
Gallo, Antonio
d’Ambrosio, Alessandro
De Stefano, Nicola
Cortese, Rosa
Valsasina, Paola
Tedone, Nicolò
Pozzilli, Carlo
Rocca, Maria A.
Filippi, Massimo
Pantano, Patrizia
,
Giannì, Costanza
Barbuti, Elena
Storelli, Loredana
Sala, Stefania
Pagani, Elisabetta
Preziosa, Paolo
Bisecco, Alvino
Borgo, Riccardo
Rippa, Valentina
Esposito, Fabrizio
Stromillo, Maria Laura
Brocci, Riccardo Tappa
Baione, Viola
Funding for this research was provided by:
Fondazione Italiana Sclerosi Multipla (2023/S/1)
Università degli Studi di Roma La Sapienza
Article History
Received: 1 September 2025
Revised: 7 November 2025
Accepted: 11 November 2025
First Online: 27 November 2025
Declarations
:
: AO, ST, FS, NP, ADA: nothing to disclose. CP: receives research support from Fondazione Italiana Sclerosi Multipla. AG: has received speaker and consulting fees from Biogen, Genzyme, Merck Serono, Mylan, Novartis, Roche, and Teva, and receives research support from Fondazione Italiana Sclerosi Multipla. NDS: has received honoraria from Biogen-Idec, Bristol Myers Squibb, Celgene, Genzyme, Immunic, Merck Serono, Novartis, Roche and Teva for consulting services, speaking, and travel support. He serves on advisory boards for Merck, Novartis, Biogen-Idec, Roche, and Genzyme, Immunic and he has received research grant support from the Italian MS Society. RC: was awarded a MAGNIMS-ECTRIMS fellowship in 2019; she received speaker honoraria from Roche, Merck Serono and Sanofi and travel support for conferences by Novartis. PV: has received speaker honoraria from Biogen Idec. CP: has served on scientific advisory boards for Novartis, Merck, Biogen, Sanofi, Genzyme, Teva, and Actelion; received funding for travel and speaker honoraria from Biogen, Teva, Sanofi Genzyme, Actelion, and Novartis; received research support from Biogen, Teva, Novartis, and Genzyme. MAR: has received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; and speaker honoraria from AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders.MF: is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. PP: has received funding for travel from Novartis, Genzyme and Bracco and speaker honoraria from Biogen.